Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.

Journal of Clinical Pharmacology
Awewura KwaraMichael H Court

Abstract

The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/d) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer. In the 26 patients studied, CYP2B6 c.516GG, GT, and TT genotype frequencies were 0.27, 0.50, and 0.23, respectively. Mean plasma efavirenz area under the curve was significantly higher in patients with CYP2B6 c.516TT than in those with GT (107 vs 27.6 microg x h/mL, P< .0001) or GG genotype (107 vs 23.0 microg x h/mL, P< .0001). Apparent oral clearance (CL/F) was significantly lower in patients with CYP2B6 c.516TT than in those with GT genotype (2.1 vs 8.4 mL/min/kg, P<0.0001) and GG genotype (2.1 vs 9.9 mL/min/kg, P< .0001). No differences in efavirenz exposure or CL/F existed between patients with CYP2B6 c.516GT and GG genotypes. Our results indicate that CYP2B6 c.516TT genotype can be used to identify efavirenz poor metabolizers in patients co-treated with rifampin.

References

Feb 7, 1998·The Journal of Clinical Investigation·R B KimG R Wilkinson
Jul 20, 2002·Clinical Pharmacokinetics·Luis F López-CortésJerónimo Pachón
Aug 2, 2002·Clinical Pharmacology and Therapeutics·Stéphane MoulyPaul B Watkins
Jan 25, 2003·Clinical Pharmacology and Therapeutics·Chantal CsajkaThierry Buclin
Feb 18, 2003·American Journal of Respiratory and Critical Care Medicine·Henry M BlumbergUNKNOWN American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society
Mar 19, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ajay MadanAndrew Parkinson
May 14, 2003·Archives of Internal Medicine·Elizabeth L CorbettChristopher Dye
Feb 24, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stephanie R FaucetteEdward L LeCluyse
Oct 13, 2004·The Journal of Infectious Diseases·Keertan DhedaMarc C Lipman
Jul 21, 2005·Clinical Pharmacokinetics·Bregt S KappelhoffJos H Beijnen
Feb 24, 2006·Pharmacogenetics and Genomics·Jue WangMagnus Ingelman-Sundberg
Apr 1, 2006·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Geetha RamachandranDavid J Greenblatt
Jul 4, 2006·Clinical Pharmacology and Therapeutics·Katarzyna K LobozAndrew J McLachlan
Aug 4, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Weerawat ManosuthiSomnuek Sungkanuparph
Oct 17, 2006·The Journal of Pharmacology and Experimental Therapeutics·Stephanie R FaucetteHongbing Wang
Jun 15, 2007·Pharmacogenomics·Zeruesenay DestaUlrich M Zanger
Oct 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hiroyuki GatanagaShinichi Oka
Oct 16, 2007·Journal of Biochemical and Molecular Toxicology·Leslie M Tompkins, Andrew D Wallace

❮ Previous
Next ❯

Citations

Nov 24, 2011·European Journal of Clinical Pharmacology·Tanuja N GengiahSalim S Abdool Karim
Nov 14, 2013·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·Susan S Schiffman, Kristina I Rother
Aug 14, 2013·AIDS Patient Care and STDs·Ignacio A Echenique, Josiah D Rich
Nov 26, 2011·BMC Research Notes·Hadija H Semvua, Gibson S Kibiki
Aug 23, 2011·Ghana Medical Journal·Jairo A Garcia A, Lewis R Roberts
Sep 22, 2009·The Journal of Antimicrobial Chemotherapy·Franco Maggiolo
May 27, 2015·The Journal of Infectious Diseases·Vaishali SahasrabudheSusanna Tse

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.